HC Wainwright Weighs in on Cibus’ Q2 Earnings (NASDAQ:CBUS)

Cibus, Inc. (NASDAQ:CBUS) – Analysts at HC Wainwright reduced their Q2 2026 earnings estimates for shares of Cibus in a research report issued to clients and investors on Friday, May 15th. HC Wainwright analyst A. Dayal now expects that the company will post earnings per share of ($0.26) for the quarter, down from their prior estimate of ($0.24). The consensus estimate for Cibus’ current full-year earnings is ($1.26) per share. HC Wainwright also issued estimates for Cibus’ Q4 2026 earnings at ($0.23) EPS, FY2026 earnings at ($1.05) EPS, FY2027 earnings at ($1.06) EPS, FY2028 earnings at ($0.49) EPS and FY2029 earnings at $0.28 EPS.

Several other research firms have also recently issued reports on CBUS. Weiss Ratings reiterated a “sell (e+)” rating on shares of Cibus in a research report on Wednesday, January 21st. Jefferies Financial Group lifted their price objective on shares of Cibus from $1.90 to $3.00 and gave the company a “hold” rating in a research report on Wednesday, March 25th. One equities research analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus price target of $9.00.

Cibus Trading Down 2.3%

NASDAQ CBUS opened at $1.28 on Tuesday. The stock has a market cap of $97.70 million, a price-to-earnings ratio of -0.65 and a beta of 1.66. Cibus has a 12 month low of $1.09 and a 12 month high of $4.19. The company’s 50 day moving average is $2.04 and its two-hundred day moving average is $1.97.

Cibus (NASDAQ:CBUS) last released its earnings results on Thursday, May 14th. The company reported ($0.33) EPS for the quarter, missing analysts’ consensus estimates of ($0.27) by ($0.06). Cibus had a negative return on equity of 200.87% and a negative net margin of 2,366.33%.The firm had revenue of $1.68 million for the quarter, compared to the consensus estimate of $1.61 million.

Institutional Investors Weigh In On Cibus

Several institutional investors and hedge funds have recently modified their holdings of CBUS. Bank of America Corp DE raised its position in shares of Cibus by 113.4% during the fourth quarter. Bank of America Corp DE now owns 35,536 shares of the company’s stock valued at $99,000 after buying an additional 18,885 shares during the last quarter. AQR Capital Management LLC bought a new stake in shares of Cibus during the first quarter valued at approximately $73,000. Qube Research & Technologies Ltd purchased a new position in shares of Cibus in the second quarter valued at $39,000. Raymond James Financial Inc. grew its holdings in shares of Cibus by 31.0% in the second quarter. Raymond James Financial Inc. now owns 53,713 shares of the company’s stock valued at $74,000 after purchasing an additional 12,722 shares in the last quarter. Finally, Jane Street Group LLC purchased a new position in shares of Cibus in the second quarter valued at $207,000. Institutional investors own 33.81% of the company’s stock.

Key Headlines Impacting Cibus

Here are the key news stories impacting Cibus this week:

• Positive Sentiment: Sidoti raised earnings estimates for several upcoming quarters, including Q2 2026, Q3 2026, Q4 2026, Q1 2027, Q2 2027, Q3 2027, and Q4 2027, suggesting a modestly better outlook for Cibus’ loss trajectory. Cibus analyst estimate update
• Positive Sentiment: Sidoti also improved its FY2027 EPS forecast for Cibus, indicating analysts see some longer-term improvement in profitability. Cibus FY2027 estimate update
• Neutral Sentiment: HC Wainwright slightly adjusted some longer-range estimates, with mixed changes across FY2026, FY2027, FY2028, and FY2029, which does not materially change the near-term investment case. Cibus HC Wainwright estimate update
• Negative Sentiment: Despite the analyst revisions, Cibus is still expected to post significant losses in the coming years, with full-year 2026 EPS consensus at -$1.26 and FY2027 still projected to be negative at about -$1.02, reinforcing concerns about profitability. Cibus profitability outlook

Cibus Company Profile

Cibus, Inc is a biotechnology company specializing in precision gene editing for agricultural applications. Leveraging its proprietary Rapid Trait Development System (RTDS), Cibus develops improved crop traits without the introduction of foreign DNA. The company’s platform enables targeted modifications to plant genomes, allowing for enhanced disease resistance, herbicide tolerance and yield optimization in key row crops.

The company’s core business centers on trait development services and licensing partnerships.